E. López-Miranda

发表

Use of bevacizumab as a first-line treatment for metastatic breast cancer.

F. Moreno, P. Zamora, B. Castelo, 2015, Current oncology.

Trastuzumab Emtansine Plus Non-Pegylated Liposomal Doxorubicin in HER2-Positive Metastatic Breast Cancer (Thelma): A Single-Arm, Multicenter, Phase Ib Trial

J. Pérez-García, T. Suter, S. Di Cosimo, 2020, Cancers.

Pembrolizumab plus eribulin in hormone-receptor-positive, HER2-negative, locally recurrent or metastatic breast cancer (KELLY): An open-label, multicentre, single-arm, phase Ⅱ trial.

G. Curigliano, J. Pérez-García, A. Prat, 2021, European journal of cancer.

Inclusion of non-inferiority analysis in superiority-based clinical trials with single-arm, two-stage Simon's design

A. Guerrero-Zotano, A. Llombart-Cussac, J. Cortés, 2019, Contemporary clinical trials communications.

Pembrolizumab Plus Gemcitabine in the Subset of Triple-Negative Advanced Breast Cancer Patients in the GEICAM/2015-04 (PANGEA-Breast) Study

F. Rojo, R. Andrés, V. Sánchez-Margalet, 2021, Cancers.

Pembrolizumab in combination with gemcitabine for patients with HER2-negative advanced breast cancer: GEICAM/2015–04 (PANGEA-Breast) study

F. Rojo, M. Ramos, R. Caballero, 2022, BMC Cancer.

Etirinotecan pegol for the treatment of breast cancer

J. Cortés, E. López-Miranda, E. Lopez-Miranda, 2016, Expert opinion on pharmacotherapy.

High Frequency of ERBB2 Activating Mutations in Invasive Lobular Breast Carcinoma with Pleomorphic Features

P. Garrido, E. Holgado, E. López-Miranda, 2019, Cancers.

Strongyloides in bronchoalveolar lavage fluid: Practical implications in the COVID-19 era

S. Chamorro, J. Pérez-Molina, F. Norman, 2021, Journal of travel medicine.

Analysis of the Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Breast Cancer Patients Treated With Cyclin-Dependent Kinases 4 and 6 Inhibitors (CDKi): Limited T-Cell Immunity Despite Satisfactory Humoral Response.

A. Carrato, F. Longo, J. Casado, 2021 .

Challenging Endocrine Sensitivity of Hormone Receptor-Positive/HER2-Negative Advanced Breast Cancer with the Combination of Eribulin and Endocrine Therapy: The REVERT Study

A. Llombart-Cussac, J. Cortés, A. Martínez-Bueno, 2022, Cancers.

Abstract P5-21-01: Cobimetinib combined with paclitaxel as first-line treatment for patients with advanced triple-negative breast cancer (COLET study): Primary analysis of cohort I

S. Loi, F. Du, D. Miles, 2018 .

Discordant Humoral and T-Cell Response to mRNA SARS-CoV-2 Vaccine and the Risk of Breakthrough Infections in Women with Breast Cancer, Receiving Cyclin-Dependent Kinase 4 and 6 Inhibitors

A. Carrato, F. Longo, J. Casado, 2023, Cancers.

First-in-human phase 1-2A study of CB-103, an oral Protein-Protein Interaction Inhibitor targeting pan-NOTCH signalling in advanced solid tumors and blood malignancies.

P. Nuciforo, D. Rossi, A. Stathis, 2018 .